Estimating the economic burden of cardiovascular events in patients receiving lipid-modifying therapy in the UK
Open accessThe DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
Objectives: To characterise the costs to the UK National Health Service of cardiovascular (CV) events among individuals receiving lipid-modifying therapy. Design: Retrospective cohort study using Clinical Practice Research Datalink records from 2006 to 2012 to identify individuals with their first and second CV-related hospitalisations (first event and second event cohorts). Within-person differences were used to estimate CV-related outcomes. Setting: Patients in the UK who had their first CV event between January 2006 and March 2012. Participants: Patients ≥18 years who had a CV event and received at least 2 lipid-modifying therapy prescriptions within 180 days beforehand. Primary and secondary outcome measures: Direct medical costs (2014 £) were estimated in 3 periods: baseline (pre-event), acute (6 months afterwards) and long-term (subsequent 30 months). Primary outcomes included incremental costs, resource usage and total costs per period. Results: There were 24 093 patients in the first event cohort of whom 5274 were included in the second event cohort. The mean incremental acute CV event costs for the first event and second event cohorts were: coronary artery bypass graft/percutaneous transluminal coronary angioplasty (CABG/PTCA) £5635 and £5823, myocardial infarction £4275 and £4301, ischaemic stroke £3512 and £4572, heart failure £2444 and £3461, unstable angina £2179 and £2489 and transient ischaemic attack £1537 and £1814. The mean incremental long-term costs were: heart failure £848 and £2829, myocardial infarction £922 and £1385, ischaemic stroke £973 and £682, transient ischaemic attack £705 and £1692, unstable angina £328 and £677, and CABG/PTCA £−368 and £599. Hospitalisation accounted for 95% of acute and 61% of long-term incremental costs. Higher comorbidity was associated with higher long-term costs. Conclusions: Revascularisation and myocardial infarction were associated with the highest incremental costs following a CV event. On the basis of real-world data, the economic burden of CV events in the UK is substantial, particularly among those with greater comorbidity burden.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Data Resource Profile: Clinical Practice Research Datalink (CPRD)
Herrett, E., Gallagher, A. M., Bhaskaran, K., Forbes, H., Mathur, R., van Staa, T., & Smeeth, L. (2015) · International Journal of Epidemiology · doi:10.1093/ije/dyv098 · Cited by 2,667 · cited 1×
“Data sources This was an observational cohort study.(11) The CPRD contains anonymised information from general practitioners (GP) on demographics, symptoms, diagnoses, test results and referrals to secondary care, and is a widely used database globally.”
BackgroundValidation and validity of diagnoses in the General Practice Research Database: a systematic review
Herrett, E., Thomas, S. L., Schoonen, W. M., Smeeth, L., & Hall, A. J. (2010) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2009.03537.x · Cited by 1,109 · cited 1×
“The CPRD data reflect the medical records of ∼6% of all patients in clinical practice in the UK, and are considered to be a very reliable source of longitudinal patient data, supporting over 1500 publications.(25) 26 Patients were included based on hospitalisations in the HES data, so they align with intense resource…”
MethodJBS3 Board (2014) · Heart · doi:10.1136/heartjnl-2014-305693 · Cited by 608
State-Transition Modeling: A Report of the ISPOR-SMDM Modeling Good Research Practices Task Force–3
Siebert, U., Alagoz, O., Bayoumi, A. M., Jahn, B., Owens, D. K., Cohen, D. J., & Kuntz, K. M. (2012) · Medical Decision Making · doi:10.1177/0272989x12455463 · Cited by 348
Straka, R. J., Liu, L. Z., Girase, P. S., DeLorenzo, A., & Chapman, R. H. (2009) · Cardiovascular Diabetology · doi:10.1186/1475-2840-8-53 · Cited by 67
Cited by
Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol
Ray, K. K., Wright, R. S., Kallend, D., Koenig, W., Leiter, L. A., Raal, F. J., Bisch, J. A., Richardson, T., Jaros, M., Wijngaard, P. L. J., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1912387 · Cited by 1,665
Self-citationMichaeli, D. T., Michaeli, J. C., Boch, T., & Michaeli, T. (2022) · Clinical Drug Investigation · doi:10.1007/s40261-022-01173-3 · Cited by 20
“Costs for the “Alive without CVD” state of £2497 per year were based on healthcare expenditure in dyslipidaemia patients without history of any cardiovascular event [26].”
BackgroundInfluentialEscobar-Cervantes, C., Villa, G., Campos-Tapias, I., Sorio-Vilela, F., Lozano, J., Kahangire, D. A., Fernandez-Delgado, M., Sicras-Navarro, A., & Sicras-Mainar, A. (2022) · Advances in Therapy · doi:10.1007/s12325-022-02187-1 · Cited by 6
Metadata
- Authors
- Danese, M. D., Gleeson, M., Kutikova, L., Griffiths, R. I., Azough, A., Khunti, K., Seshasai, S. R. K., & Ray, K. K.
- Venue
- BMJ Open
- Publisher
- BMJ
- Published
- 2016-08
- Volume
- 6
- Issue
- 8
- Pages
- e011805
- ISSN
- 2044-6055 (ISSN-L)
- OpenAlex
- W2477902079
- Cited by
- 41
- References
- 5
- FWCI
- 3.98
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.